– Company seeks proposals to create and sustain community-focused programs to support underserved populations with these conditions –
VICTORIA, British Columbia & ROCKVILLE, Md.–(BUSINESS WIRE)–Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today, affirmed its commitment to individuals living with the systemic lupus erythematosus (SLE) and lupus nephritis (LN) through the sponsorship of charitable grants to establish or expand community-focused patient navigator programs. This is the second year of this unique program aimed at eliminating barriers to care for individuals living with SLE/LN. LN is a serious manifestation of SLE that can cause irreversible kidney damage and kidney failure and significantly affects more Black, Asian, and Hispanic individuals than non-Hispanic White individuals. Selected applicants may receive up to $50,000 over a one-year period.